MA39847A - Protéines de liaison à l'antigène se liant à wisp1 - Google Patents

Protéines de liaison à l'antigène se liant à wisp1

Info

Publication number
MA39847A
MA39847A MA039847A MA39847A MA39847A MA 39847 A MA39847 A MA 39847A MA 039847 A MA039847 A MA 039847A MA 39847 A MA39847 A MA 39847A MA 39847 A MA39847 A MA 39847A
Authority
MA
Morocco
Prior art keywords
antibodies
wisp1
derivatives
polypeptides
methods
Prior art date
Application number
MA039847A
Other languages
English (en)
Inventor
Gunnar F Kaufmann
Heyue Zhou
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MA39847A publication Critical patent/MA39847A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des compositions et des méthodes se rapportant ou dérivées d'anticorps anti-wisp1. Plus spécifiquement, cette invention concerne des anticorps entièrement humains qui se lient à wisp1, des fragments d'anticorps qui se lient à wisp1, des dérivés desdits anticorps, et des polypeptides contenant lesdits fragments qui se lient à wisp1. D'autres modes de réalisation encore concernent des acides nucléiques codant pour ces anticorps, fragments d'anticorps, dérivés et polypeptides, des cellules contenant lesdits polynucléotides, des procédés de préparation des anticorps, fragments d'anticorps, dérivés et polypeptides selon l'invention, et des méthodes pour les utiliser comprenant des méthodes destinées à traiter ou à diagnostiquer les sujets présentant des troubles ou des états pathologiques associés à wisp1. Une méthode destinée à traiter ou à prévenir divers cancers ou maladies inflammatoires et diverses maladies du cœur, des os/articulations ou du poumon est en outre décrite.
MA039847A 2014-04-15 2015-04-14 Protéines de liaison à l'antigène se liant à wisp1 MA39847A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461979704P 2014-04-15 2014-04-15

Publications (1)

Publication Number Publication Date
MA39847A true MA39847A (fr) 2017-02-22

Family

ID=54324703

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039847A MA39847A (fr) 2014-04-15 2015-04-14 Protéines de liaison à l'antigène se liant à wisp1

Country Status (9)

Country Link
US (2) US10272154B2 (fr)
EP (1) EP3131574A4 (fr)
JP (1) JP2017513854A (fr)
KR (1) KR20160138580A (fr)
CN (1) CN106456732A (fr)
AU (1) AU2015247742A1 (fr)
CA (1) CA2945498A1 (fr)
MA (1) MA39847A (fr)
WO (1) WO2015160858A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160138580A (ko) 2014-04-15 2016-12-05 소렌토 쎄라퓨틱스, 인코포레이티드 Wisp1에 결합하는 항원 결합 단백질
JP6987068B2 (ja) * 2015-11-09 2021-12-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 癌マーカーおよび治療標的としてのグリピカン2
CN108663524B (zh) * 2018-05-18 2021-06-25 南昌大学第二附属医院 过表达FAT10扰乱WISP1蛋白和mRNA表达促进肝癌的进展
WO2020033398A1 (fr) * 2018-08-06 2020-02-13 The Trustees Of Columbia University In The City Of New York Compositions et procédés pour le traitement de maladies pulmonaires dépendant de cellules atii
AU2019361120A1 (en) * 2018-10-19 2021-05-13 The General Hospital Corporation Compositions and methods for treatment of liver disease
CN109535249B (zh) * 2018-12-12 2021-06-01 广州市第八人民医院 一种单克隆抗体ZKns3G2及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2306183A1 (fr) * 1997-10-29 1999-05-06 Genentech, Inc. Polypeptides a secretion induite par wnt-1, et notamment les proteines wisp-1, -2 et -3
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SI2809681T1 (sl) * 2012-01-31 2019-04-30 Regeneron Pharmaceuticals, Inc. Protitelesa anti-asic1 in njihova uporaba
KR20160138580A (ko) 2014-04-15 2016-12-05 소렌토 쎄라퓨틱스, 인코포레이티드 Wisp1에 결합하는 항원 결합 단백질

Also Published As

Publication number Publication date
EP3131574A4 (fr) 2018-01-03
EP3131574A2 (fr) 2017-02-22
US20190224316A1 (en) 2019-07-25
JP2017513854A (ja) 2017-06-01
WO2015160858A3 (fr) 2015-12-17
US20170304442A1 (en) 2017-10-26
CN106456732A (zh) 2017-02-22
CA2945498A1 (fr) 2015-10-22
AU2015247742A1 (en) 2016-11-24
US11318202B2 (en) 2022-05-03
WO2015160858A2 (fr) 2015-10-22
US10272154B2 (en) 2019-04-30
KR20160138580A (ko) 2016-12-05

Similar Documents

Publication Publication Date Title
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
WO2017015560A3 (fr) Anticorps thérapeutiques qui se lient à lag3
WO2014194302A3 (fr) Protéines de liaison à l'antigène qui se lient à pd-1
MX2017011406A (es) Terapeuticos de anticuerpo que se unen a tim3.
MA39847A (fr) Protéines de liaison à l'antigène se liant à wisp1
WO2013181634A3 (fr) Protéines liant un antigène qui lient pd-l1
MX2021007947A (es) Terapeuticos de anticuerpo que se unen a ctla4.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2017010793A (es) Terapeuticos de anticuerpo que ligan cd137.
WO2013192596A3 (fr) Protéines de liaison à un antigène qui se lient à ccr2
MX2017011329A (es) Productos terapeuticos de anticuerpos que se enlazan a cd47.
WO2016164669A3 (fr) Agents thérapeutiques de type anticorps se liant à cd38
WO2013192594A3 (fr) Protéines de liaison à un antigène qui se lient à c-met
JO3623B1 (ar) البروتينات المرتبطة بمولد المستضاد st2
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
PH12019500571A1 (en) Anti-pd-1 antibodies
MY200162A (en) Anti-gitr antibodies and uses thereof
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
WO2014066530A3 (fr) Protéines de liaison à un antigène qui se lient à erbb3
WO2014062245A3 (fr) Protéines liant l'antigène qui lient dll-4
WO2016164657A3 (fr) Agents thérapeutiques de type anticorps se liant à cd123
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2017015690A (es) Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
WO2016063026A3 (fr) Séquences de liaison sélectives pour la protéine nav